Advertisement
Selected topic: Toxicology| Volume 39, ISSUE 5, P607-611, November 2010

Safety and Effectiveness of Acetadote for Acetaminophen Toxicity

  • Allyson J. Whyte
    Affiliations
    Department of Emergency Medicine, University of Pittsburgh Medical Center, Presbyterian Hospital, Pittsburgh, Pennsylvania
    Search for articles by this author
  • Thompson Kehrl
    Affiliations
    Department of Emergency Medicine, University of Pittsburgh Medical Center, Presbyterian Hospital, Pittsburgh, Pennsylvania
    Search for articles by this author
  • Daniel E. Brooks
    Affiliations
    Department of Emergency Medicine, University of Pittsburgh Medical Center, Presbyterian Hospital, Pittsburgh, Pennsylvania

    Division of Medical Toxicology, University of Pittsburgh Medical Center, Presbyterian Hospital, Pittsburgh, Pennsylvania
    Search for articles by this author
  • Kenneth D. Katz
    Correspondence
    Reprint Address: Kenneth D. Katz, md, Department of Emergency Medicine, University of Pittsburgh Medical Center, 230 McKee Place, Suite 500, Pittsburgh, PA 15213
    Affiliations
    Department of Emergency Medicine, University of Pittsburgh Medical Center, Presbyterian Hospital, Pittsburgh, Pennsylvania

    Division of Medical Toxicology, University of Pittsburgh Medical Center, Presbyterian Hospital, Pittsburgh, Pennsylvania
    Search for articles by this author
  • Devin Sokolowski
    Affiliations
    University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
    Search for articles by this author
Published:November 21, 2008DOI:https://doi.org/10.1016/j.jemermed.2008.05.007

      Abstract

      Background: Acetaminophen (APAP) toxicity is commonly encountered in the Emergency Department. Until 2004, treatment consisted of either oral N-acetylcysteine (NAC) or filtered oral NAC administered intravenously (i.v.). Intravenous acetylcysteine (Acetadote) is a new Food and Drug Administration-approved i.v. formulation of acetylcysteine manufactured by Cumberland Pharmaceuticals in Nashville, Tennessee. Little post-marketing data exists on the effectiveness and safety of i.v. acetylcysteine. Objectives: We evaluated the clinical presentations and outcomes of patients treated with i.v. acetylcysteine for APAP toxicity. Methods: We performed a retrospective chart review of patients treated with i.v. acetylcysteine for APAP ingestion. The primary outcome measures were: adverse reactions to and effectiveness of i.v. acetylcysteine, as defined by elevation of transaminases, liver failure, renal failure, death, and hospital length of stay (LOS). Data collected included: comorbidities, allergies, intentionality, timing and dosing of i.v. acetylcysteine, hospital LOS, transaminases > 1000 IU/L, development of liver failure requiring transplant, development of renal failure requiring hemodialysis, death, and anaphylactoid reactions. Results: Sixty-four patients met our study criteria. Overall, 16 (25%) patients developed transaminases > 1000 IU/L, 4 (6%) of them died and 2 (3%) received liver transplants. Of the 15 patients (23%) treated within 8 h, none died or developed liver or renal failure, and only 1 developed transient transaminase elevation > 1000 IU/L. In the patients treated outside of 8 h, the median LOS was 3 days, whereas the group treated within 8 h had a median LOS of only 1 day. Six (9%) patients developed anaphylactoid reactions, 2 of whom received the i.v. acetylcysteine bolus over 15 min. Five of these patients were treated pharmacologically and completed treatment, and one had treatment discontinued for undocumented reasons. Conclusion: Intravenous acetylcysteine seemed to be a safe and effective formulation of N-acetylcysteine.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Emergency Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lai M.W.
        • Klein-Schwartz W.
        • Rogers G.C.
        • et al.
        2005 Annual Report of the American Association of Poison Control Centers' national poisoning and exposure database.
        Clin Toxicol (Phila). 2006; 44: 803-932
        • Ostapowicz G.
        • Fontana R.J.
        • Schiødt F.V.
        • et al.
        Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States.
        Ann Intern Med. 2002; 137: 947-954
        • Perry H.E.
        • Shannon M.W.
        Efficacy of oral versus intravenous N-acetylcysteine in acetaminophen overdose: results of an open-label clinical trial.
        J Pediatr. 1998; 132: 149-152
        • Buckley N.A.
        • Whyte I.M.
        • O'Connell D.L.
        • Dawson A.H.
        Oral or intravenous N-acetylcysteine: which is the treatment of choice for acetaminophen (paracetamol) poisoning?.
        J Toxicol Clin Toxicol. 1999; 37: 759-767
        • Smilkstein J.M.
        • Bronstein A.C.
        • Linden C.
        • Augenstein W.L.
        • Kulig K.W.
        • Rumack B.H.
        Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine treatment protocol.
        Ann Emerg Med. 1991; 20: 1058-1063
        • Rumack B.H.
        • Peterson R.G.
        Acetaminophen overdose: Incidence, diagnosis and management in 416 patients.
        Pediatrics. 1978; 62: 898-903
        • Rumack B.H.
        • Peterson R.C.
        • Koch G.G.
        • Amara I.A.
        Acetaminophen overdose: 662 cases with evaluation of oral acetylcysteine treatment.
        Arch Intern Med. 1981; 141: 380-385
        • Miners J.O.
        • Drew R.
        • Birkett D.J.
        Mechanism of action of paracetamol protective agents in mice in vivo.
        Biochem Pharmacol. 1984; 33: 2995-3000
        • Smilkstein M.J.
        • Knapp G.L.
        • Kulig K.W.
        • Rumack B.H.
        Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose: analysis of the National Multicenter Study (1976 to 1985).
        N Engl J Med. 1988; 319: 1557-1562
        • Tenenbein M.
        Hypersensitivity-like reactions to N-acetylcysteine.
        Vet Hum Toxicol. 1984; 26: 3-5
        • Yip L.
        • Dart R.C.
        • Hurlbut K.M.
        Intravenous administration of oral N-acetylcysteine.
        Crit Care Med. 1998; 26: 40-43
        • Borys D.J.
        • Jackson T.W.
        • Jacobs M.R.
        Intravenous N-acetylcysteine, use of an unapproved drug product: a two-year retrospective review [abstract].
        Vet Hum Toxicol. 1992; 24: 327
        • Kao L.W.
        • Kirk M.A.
        • Furbee R.B.
        • Mehta N.H.
        • Skinner J.R.
        • Brizendine E.J.
        What is the rate of adverse events after oral N-acetylcysteine administered by the intravenous route to patients with suspected acetaminophen poisoning?.
        Ann Emerg Med. 2003; 47: 741-750
        • Lynch R.M.
        • Robertson R.
        Anaphylactoid reactions to intravenous N-acetylcysteine: a prospective case controlled study.
        Accid Emerg Nurs. 2004; 12: 10-15